drugset
drugset / Trial / NCT01626885

A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia

NCT01626885 ↗

Phase 2/3 Completed 42 enrolled Tanabe Pharma Corporation
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with receiving multiple drugs schizophrenia.

Timeline

Start
2012-05
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 1.5 mg Oral
Subject Cariprazine Small molecule 9 mg Oral

Indications

schizophrenia